All the news Showing 10 of 51 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Fatty liver greatly increases vulnerability to COVID-19 in obese people Keith Alcorn / 16 November 2020 Fatty liver disease combined with obesity places people at much higher risk of severe COVID-19, analysis of British people who tested positive for SARS-CoV-2 shows. Obesity alone did not increase the risk ... Cotadutide improves metabolic and liver biomarkers in people with NAFLD and diabetes Liz Highleyman / 26 October 2020 Cotadutide, an experimental therapy that alters glucose and lipid metabolism, led to weight loss and improvements in metabolic, cardiovascular and liver fibrosis biomarkers in overweight people with diabetes and fatty liver disease, but ... Experimental NASH treatments: Gilead candidates miss primary endpoint but show some benefits Liz Highleyman / 20 October 2020 Combinations of experimental drugs for non-alcoholic steatohepatitis (NASH) failed to meet a study's primary endpoint by significantly improving liver fibrosis without worsening NASH, but one combination in particular – firsocostat plus ... Fatty liver disease common in people living with HIV and hepatitis B Keith Alcorn / 30 September 2020 Around one in three people with HIV and hepatitis B had fatty liver disease and one in ten had liver damage, US researchers from the Hepatitis B Research Network report in Clinical ... Diabetes raises the risk of liver damage in people with HIV Keith Alcorn / 21 September 2020 Almost half of people with HIV with unexplained liver enzyme elevations or other abnormal liver markers had non-alcoholic steatohepatitis (NASH) and 39 of 116 had stage F3 or F4 fibrosis, and advanced ... Aldafermin reduces liver fat in phase 2 study Keith Alcorn / 14 September 2020 Aldafermin significantly reduced liver fat content and liver damage in a phase 2 study of a 24-week treatment course, Dr Stephen Harrison, Visiting Professor of Hepatology at the University of Oxford, told ... Fatty liver disease affects one in four in Europe, study estimates Keith Alcorn / 07 September 2020 Non-alcoholic fatty liver disease affects one in four people in the general population in Europe and just over one in twenty people have advanced liver fibrosis, a meta-analysis of 33 studies from ... NASH is fastest-growing reason for a liver transplant in United States Keith Alcorn / 22 June 2020 Non-alcoholic steatohepatitis (NASH), the severe form of non-alcoholic fatty liver disease (NAFLD), is now the most common reason for a liver transplant in women, older patients and people receiving Medicare insurance in the ... Non-alcoholic fatty liver disease does not raise the risk of COVID-19, gene study shows Keith Alcorn / 26 May 2020 People with a genetic profile that strongly predicts non-alcoholic or metabolic-associated fatty liver disease were not at higher risk of being hospitalised with COVID-19 in the United Kingdom, an analysis of the ... Non-alcoholic fatty liver disease affects a quarter of lean people living with HIV Michael Carter / 13 May 2020 A quarter of people living with HIV with normal body weight have non-alcoholic-fatty liver disease (NAFLD), Italian and Canadian investigators report in Clinical Infectious Diseases. Risk factors were older age, ... ← Prev12345...6Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive